



US010335462B2

(12) **United States Patent**
Jensen

(10) **Patent No.:** **US 10,335,462 B2**

(45) **Date of Patent:** ***Jul. 2, 2019**

- (54) **USE OF LONG-ACTING GLP-1 PEPTIDES**
- (71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)
- (72) Inventor: **Christine Bjoern Jensen**, Charlottenlund (DK)
- (73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

RU	2413530	C2	3/2011
WO	2006/097537	A2	9/2006
WO	2010/092163	A2	8/2010
WO	2011/080103	A1	7/2011
WO	2011/138421	A1	11/2011
WO	12016419	A1	2/2012
WO	2012/080471	A1	6/2012
WO	2012/107476	A1	8/2012
WO	12130136	A1	10/2012
WO	12136790	A1	10/2012
WO	2012/177929	A2	12/2012

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/656,042**

(22) Filed: **Jul. 21, 2017**

(65) **Prior Publication Data**

US 2018/0085435 A1 Mar. 29, 2018

Related U.S. Application Data

(63) Continuation of application No. 14/409,493, filed as application No. PCT/EP2013/063004 on Jun. 21, 2013, now Pat. No. 9,764,003.

(60) Provisional application No. 61/708,162, filed on Oct. 1, 2012, provisional application No. 61/694,837, filed on Aug. 30, 2012.

(30) **Foreign Application Priority Data**

Jul. 1, 2012	(EP)	12174535
Oct. 1, 2012	(EP)	12186781

(51) **Int. Cl.**

A61K 38/26	(2006.01)
A61P 5/50	(2006.01)
A61P 3/04	(2006.01)
A61P 3/10	(2006.01)

(52) **U.S. Cl.**

CPC **A61K 38/26** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,129,343	B2	3/2012	Lau et al.
8,536,122	B2	9/2013	Lau et al.
2010/0047762	A1	2/2010	Button et al.
2010/0292133	A1	11/2010	Spetzler et al.
2011/0301080	A1	12/2011	Bush et al.

FOREIGN PATENT DOCUMENTS

CN	102229668	A	11/2011
RU	2409349	C2	1/2011

OTHER PUBLICATIONS

Madsbad S et al. An Overview of once-weekly glucagon-like peptide-1 receptor agonists available efficacy and safety data and perspectives for the future, *Diabetes, Obesity and Metabolism* Year 2011, vol. 13, No. 5, pp. 394-407.

Buse B. J. et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, *Lancet*, 2013, vol. 381, pp. 117-124.

Kim et al. "Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exentide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes." *Diabetes care* (2007) vol. 30 pp. 1487-1493.

Bydureon NDA 022200/S-008 Package Information pp. 1-179 (Feb. 2014).

Clinical Trial NCT00696657 entitled "A Randomized Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide." pp. 1-5 Mar. 2015. Accessed Sep. 24, 2015 at clinicaltrials.gov/archive/NCT00696657/2011_03_25.

Lau et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." *J. Med. Chem.* (2015) vol. 58 pp. 7370-7380.

Eperzan Assessment Report. Euro. Med. Agency. pp. 1-124 (2014) accessed Sep. 24, 2015 at URL ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002735/WC500165119.pdf.

Trulicity Assessment Report. Euro. Med. Agency. pp. 1-172 (2014) accessed Sep. 24, 2015 at URL ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf.

Mizuta et al. "The Role for GLP-1 in Regulation of Body Weight." *Progress in Medicine* 2008 vol. 28 No. 8 pp. 1909-1912.

CDC, "National Health and Nutrition Examination Survey: Healthy Weight, Overweight and Obesity among U.S. adults" 03-0260 pp. 1-2 (Jul. 2003), accessed May 10, 2016 at URL cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf.

Primary Examiner — Julie Ha

Assistant Examiner — Kristina M Hellman

(74) *Attorney, Agent, or Firm* — Leon Y. Lum

(57) **ABSTRACT**

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

10 Claims, 6 Drawing Sheets

Specification includes a Sequence Listing.




Fig. 1




Fig. 2




Fig. 3A




Fig. 3 B

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.